merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>The primary reason for the skepticism surrounding the approval of Kisunla is the lack of correlation between amyloid plaque removal and clinical response in individual patients, as well as the potential safety risks, including swelling and bleeding in the brain.</answer>

<question_number>2</question_number>
<answer>The article suggests that the focus on anti-amyloid drugs might discourage patients from participating in trials for treatments that could be better, potentially slowing progress in the field.</answer>

<question_number>3</question_number>
<answer>According to Dr. Greicius, there is no correlation between the removal of amyloid plaques and the clinical response in individual subjects.</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>The article suggests that the cost of Kisunla might be justified despite its higher price compared to Leqembi because patients can potentially discontinue treatment after their plaques are cleared, reducing the overall cost and inconvenience of treatment.</answer>

<question_number>6</question_number>
<answer>N/A</answer>

<question_number>7</question_number>
<answer>The article explains that Kisunla can reduce the inconvenience of treatment compared to Leqembi because patients can potentially discontinue treatment after their plaques are cleared, reducing the need for ongoing infusions.</answer>

<question_number>8</question_number>
<answer>Amyloid</answer>

<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>

<question_number>10</question_number>
<answer>The factor in the donanemab trial that suggests treating patients earlier in the disease progression might be more effective is that trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels.</answer>